4,6-二氯-1-乙基-1H-吡唑并[3,4-d]嘧啶 | 864292-48-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 4,6-二氯-1-乙基-1H-吡唑并[3,4-d]嘧啶
• 英文名称: 4,6-dichloro-1-ethylpyrazolo[3,4-d]pyrimidine
• 英文别名: 4,6-dichloro-1-ethyl-1H-pyrazolo[3,4-d]pyrimidine
• CAS: 864292-48-8
• 化学式: C₇H₆Cl₂N₄
• 分子量: 217.057
• InChiKey: MBSDYSAYKSKMQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4,6-二氯-1-乙基-1H-吡唑并[3,4-d]嘧啶 、 8-氧代-3-杂氮二环[3,2,1]辛烷盐酸盐 在 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 6-Chloro-1-ethyl-4-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability

  摘要：

  A series of highly potent and selective pyrazolopyrimidine mTOR inhibitors which contain water-solubilizing groups attached to the 6-arylureidophenyl moiety have been prepared. Such derivatives displayed superior potency to those in which these appendages were attached to alternative sites. In comparison to unfunctionalized arylureido compounds, these analogs demonstrated enhanced cellular potency and significantly improved stability towards human microsomes, resulting in an mTOR inhibitor with impressive efficacy in a xenograft model with an intermittent dosing regimen. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.096
• 作为产物：
  描述：

  1-ethyl-1,7-dihydro-pyrazolo[3,4-d]pyrimidine-4,6-dione 在 五氯化磷 作用下， 以 三氯氧磷 为溶剂， 反应 36.0h， 生成 4,6-二氯-1-乙基-1H-吡唑并[3,4-d]嘧啶
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS DE PYRAZOLOPYRIMIDINE INHIBANT PI3K ET PROCÉDÉS D'UTILISATION

  摘要：

  式I的化合物，包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和其药用可接受的盐，用于抑制脂质激酶，包括p110α和PI3K的其他同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用式I的化合物进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。【式I】

  公开号：

  WO2009097446A1

文献信息

• Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent
  作者：Kevin J. Curran、Jeroen C. Verheijen、Joshua Kaplan、David J. Richard、Lourdes Toral-Barza、Irwin Hollander、Judy Lucas、Semiramis Ayral-Kaloustian、Ker Yu、Arie Zask

  DOI：10.1016/j.bmcl.2009.12.086

  日期：2010.2

  A series of pyrazolopyrimidine mammalian Target Of Rapamycin (mTOR) inhibitors with various substituents at the 1-position have been prepared, resulting in compounds with excellent potency, selectivity and microsomal stability. Combination of a 1-cyclohexyl ketal group with a 2,6-ethylene bridged morpholine in the 4-position and a ureidophenyl group in the 6-positon resulted in compound 8a, that selectively

  制备了一系列吡唑并嘧啶的哺乳动物雷帕霉素靶标（mTOR）抑制剂，这些抑制剂在1位具有多个取代基，从而产生具有出色效价，选择性和微粒体稳定性的化合物。将1-环己基缩酮基团与4-位的2,6-乙烯桥连吗啉和6-位脲基上的脲基苯基基团结合，可产生化合物8a，其在体内选择性抑制关键的mTOR生物标记至少8 h静脉给药并在异种移植肿瘤模型中显示出优异的口服活性。
• [EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES EN TANT QU'INHIBITEURS DE L'ACTIVITÉ DE BCDIN3D
  申请人：STORM THERAPEUTICS LTD

  公开号：WO2020254831A1

  公开（公告）日：2020-12-24

  The present invention relates to compounds that function as inhibitors and/or degraders of BCDIN3D activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCDIN3D activity is implicated.

  本发明涉及作为BCDIN3D活性抑制剂和/或降解剂的化合物。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增生性疾病，如癌症，以及其他BCDIN3D活性有所涉及的疾病或病况中的应用。
• PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Dotson Jennafer

  公开号：US20110172216A1

  公开（公告）日：2011-07-14

  Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  具有I式化合物的立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药物可接受的盐，对于抑制脂质激酶包括p110α和其他PI3K同工酶以及治疗由脂质激酶介导的癌症等疾病是有用的。公开了使用I式化合物的方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗这种疾病，或相关的病理条件。
• Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
  申请人：Dotson Jennafer

  公开号：US08987280B2

  公开（公告）日：2015-03-24

  Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  式I的化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药学上可接受的盐，对于抑制脂质激酶包括p110 alpha和PI3K的其他同系物，并用于治疗由脂质激酶介导的癌症等疾病具有用处。揭示了使用式I的化合物进行哺乳动物细胞中的体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY
  申请人：Storm Therapeutics Ltd

  公开号：EP3986568A1

  公开（公告）日：2022-04-27